Creon Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

This Creon market report delivers an in-depth analysis of the market’s key characteristics, including size, growth potential, and segmentation. It provides a detailed breakdown of the market across major regions and leading countries, highlighting historical data and future growth projections. The report also examines the competitive landscape, market share insights, emerging trends, and strategic developments shaping the market.

Market growth during the historic period can be attributed to factors such as the increased use of pancrelipase for treating digestive disorders, higher purchasing power, greater awareness of pancrelipase usage, a rise in the incidence of pancreatic conditions, and an increase in chronic pancreatitis cases.

Market growth during the forecast period driven by factors such as a rising demand for specialized enzyme replacement therapies, a growing emphasis on personalized medicine, the impact of unhealthy diets, an expanding geriatric population, and increasing healthcare expenditures. Key trends expected in the forecast period include advancements in enteric coating technology, AI-driven innovations, technological improvements in drug delivery, and a continued shift toward personalized medicine.

The increasing prevalence of pancreatic disorders is expected to drive the growth of the creon market. Pancreatic disorders are a group of conditions that affect the pancreas, disrupting its ability to produce digestive enzymes and/or insulin, which leads to digestive issues, blood sugar regulation problems, and overall health complications. Factors contributing to the rising prevalence include higher rates of chronic alcohol consumption, smoking, obesity, diabetes, genetic predispositions, and advancements in diagnostic techniques. Creon is used to manage these disorders by supplementing digestive enzymes, aiding nutrient digestion and absorption. For example, in February 2023, Cancer Research UK projected that the number of new pancreatic cancer cases in the UK would rise from approximately 12,500 annually between 2023 and 2025 to around 16,000 cases by 2038-2040. It is expected that the incidence of pancreatic cancer will increase by 5% over this period. As such, the growing prevalence of pancreatic disorders is driving creon market growth.

The expanding demand for personalized medicine is expected to fuel the growth of the creon market. Personalized medicine tailors treatment based on an individual’s genetic makeup, environment, and lifestyle, optimizing effectiveness while minimizing side effects. This approach is gaining momentum due to advancements in genetics, a deeper understanding of diseases, the demand for more effective treatments, and the use of technology such as AI to develop customized therapies. Personalized medicine enhances Creon’s effectiveness by enabling more precise enzyme replacement therapy suited to the specific needs of individual patients with pancreatic conditions. For example, in February 2024, the Personalized Medicine Coalition reported that the FDA approved 16 new personalized treatments for rare diseases in 2023, a notable increase from the six approvals in 2022. Thus, the growing emphasis on personalized medicine is contributing to the expansion of the creon market.

Rising healthcare expenditure is expected to drive the growth of the creon market. Healthcare expenditure refers to the total spending on medical services, treatments, pharmaceuticals, and healthcare infrastructure. It has been increasing due to factors such as aging populations, higher demand for medical services, increased treatment costs, and technological advancements in healthcare. This expenditure plays a crucial role in making Creon accessible and affordable for patients with pancreatic disorders, directly influencing its availability and use. For instance, in December 2023, the U.S. Centers for Medicare & Medicaid Services reported that healthcare spending in the U.S. grew by 4.1% in 2022, reaching $4.5 trillion, surpassing the previous year's growth rate of 3.2%. Spending on hospital care services, clinical and physician services, and retail prescription drugs all saw significant increases. Therefore, rising healthcare expenditure is driving the growth of the creon market.

The key company operating in the creon market is AbbVie Inc.

North America was the largest region in the creon market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in creon report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the creon market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Creon is a prescription medication that contains pancrelipase, a mixture of digestive enzymes including lipase, protease, and amylase, which are typically produced by the pancreas to aid in food digestion. It is used to treat conditions where the pancreas fails to produce sufficient enzymes, such as cystic fibrosis, chronic pancreatitis, or following pancreatic surgery. By supplementing the body’s enzyme levels, Creon helps improve the digestion and absorption of essential nutrients such as fats, proteins, and carbohydrates. It is taken orally with meals and snacks to support digestion.

The primary uses of creon include nutritional management and pancreatic enzyme replacement therapy (PERT). Nutritional management involves planning and controlling a person’s diet to support health, recovery, and overall well-being. Creon is used to treat symptoms such as abdominal pain, constipation, diarrhea, fatty stools, and weight loss. It is available through hospital pharmacies, retail pharmacies, and online pharmacies.

The creon market research report is one of a series of new reports that provides creon market statistics, including creon industry global market size, regional shares, competitors with a creon market share, detailed creon market segments, market trends and opportunities, and any further data you may need to thrive in the creon industry. This creon market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The creon market consists of sales of pancreatic enzyme supplements, digestive health supplements, pancreatic enzyme replacement therapy (PERT) devices, and nutritional supplements for digestive health. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.